ReviewCardiology research and practice2026
Latest Management of Cardiac Sarcoidosis: A Comprehensive Review.
Review in Cardiology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latest Management of Cardiac Sarcoidosis: A Comprehensive Review.Cardiology research and practice · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiac sarcoidosis (CS) is a rare but serious manifestation of sarcoidosis. Its complications might include high-grade conduction blocks, atrial and ventricular arrhythmias, and even heart failure. Despite its clinical significance, it exhibits a heterogeneous presentation that makes its diagnosis and management challenging. In this review, we aim to address the different management options of CS, encompassing pharmacotherapy, implantable devices, lifestyle modifications, and surgical interventions. Research findings suggested a positive role of corticosteroids in alleviating the inflammation associated with CS while also improving cardiac parameters. However, given their serious side effects, the use of steroid-sparing medications was also supported. In addition, device-based interventions and ablation were effective in managing the increased risk of arrhythmias and heart failure-associated CS. The importance of lifestyle modifications was tackled as a simultaneous treatment option along with the above. Still, interindividual variability and the absence of strict guidelines were major challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.